Description: Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) powered image-analysis software to enhance the detection and management of coronary artery disease. It offers Salix, a cloud-based software that uses its proprietary AI algorithms to interpret data from coronary computed tomography angiography scans and delivers findings in a single point of care solution. The company's Salix suite comprises Salix Coronary Anatomy and Salix Coronary Flow. It serves radiologists and cardiologists worldwide. The company was founded in 2018 and is based in Crawley, Australia.
Home Page: www.artrya.com
AYA Technical Analysis
1257 Hay Street
West Perth,
WA
6005
Australia
Phone:
61 8 6478 7816
Officers
| Name | Title |
|---|---|
| Mr. John Windsor Barrington A.M., F.A.C.I.D., M.B.A. | Co-founder, CEO, MD & Director |
| Mr. John Konstantopoulos B.E. | Co-Founder, Exec. Director of Product & Director |
| Mr. Mark Wainwright | Chief Financial Officer |
| Dr. Julien Flack | Chief Technology Officer |
| Prof. Girish Dwivedi M.D. | Chief Scientific Officer |
| Ms. Janice Marcon | Chief People & Culture Officer |
| Dr. Jacob Agris M.D., Ph.D. | Chief Medical Officer |
| Mr. Riaz Kingston | Head of Bus. Devel. |
| Dr. Jacque J. Sokolov B.A., M.D. | Non-Exec. Director, Chair & Pres of Artrya USA Inc |
| Mr. Ted Schwab | Co-CEO of Artrya USA Inc |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8489 |
| Price-to-Sales TTM: | 163.1758 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |